HIV-1 Envelope Proteins and V1/V2 Domain Scaffolds with Mannose-5 to Improve the Magnitude and Quality of Protective Antibody Responses to HIV-1

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

(2013) Hua-Xin Liao et al.   IMMUNITY

HIV-1 neutralizing antibodies: understanding nature's pathways

(2013) John R. Mascola et al.   IMMUNOLOGICAL REVIEWS

Neutralizing antibodies to HIV-1 induced by immunization

(2013) Laura E. McCoy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Chemical Synthesis of Highly Congested gp120 V1V2 N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines

(2013) Baptiste Aussedat et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes

(2013) S. Hoffenberg et al.   JOURNAL OF VIROLOGY

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies

(2013) Mohammed N Amin et al.   Nature Chemical Biology

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

(2013) Marie Pancera et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

(2013) Leopold Kong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

(2013) Susan Zolla-Pazner et al.   PLoS One

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors

(2013) S. M. Alam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9

(2013) Jean-Philippe Julien et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

(2013) J.-P. Julien et al.   SCIENCE

Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

(2013) D. Lyumkis et al.   SCIENCE

Novel directions in HIV-1 vaccines revealed from clinical trials

(2013) Jean-Louis Excler et al.   Current Opinion in HIV and AIDS

A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

(2013) Rogier W. Sanders et al.   PLoS Pathogens

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

(2012) Nicos Karasavvas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Blueprint for HIV Vaccine Discovery

(2012) Dennis R. Burton et al.   Cell Host & Microbe

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

(2012) Mattia Bonsignori et al.   JOURNAL OF VIROLOGY

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

(2012) M. Bonsignori et al.   JOURNAL OF VIROLOGY

Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

(2012) S. Munir Alam et al.   JOURNAL OF VIROLOGY

A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies

(2012) N. A. Doria-Rose et al.   JOURNAL OF VIROLOGY

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

(2012) Morgane Rolland et al.   NATURE

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

(2012) Jinghe Huang et al.   NATURE

Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape

(2012) Penny L Moore et al.   NATURE MEDICINE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding

(2012) Gerald R. Nakamura et al.   PLoS One

Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials

(2012) Bin Yu et al.   PLoS One

Cross-reactive broadly neutralizing antibodies: timing is everything

(2012) Zelda Euler et al.   Frontiers in Immunology

Fundamental Characteristics of the Immunoglobulin VH Repertoire of Chickens in Comparison with Those of Humans, Mice, and Camelids

(2011) L. Wu et al.   JOURNAL OF IMMUNOLOGY

Binding Interactions between Soluble HIV Envelope Glycoproteins and Quaternary-Structure-Specific Monoclonal Antibodies PG9 and PG16

(2011) T. M. Davenport et al.   JOURNAL OF VIROLOGY

Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors

(2011) M. Bonsignori et al.   JOURNAL OF VIROLOGY

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

(2011) Jason S. McLellan et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade

(2011) Camille Bonomelli et al.   PLoS One

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

(2011) R. Pejchal et al.   SCIENCE

The cost-effectiveness of a modestly effective HIV vaccine in the United States

(2011) Elisa F. Long et al.   VACCINE

The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand

(2011) Kyeen M. Andersson et al.   VACCINE

HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem

(2011) Wayne C. Koff   VACCINE

Methods development for analysis of partially deglycosylated proteins and application to an HIV envelope protein vaccine candidate

(2010) Eden P. Go et al.   INTERNATIONAL JOURNAL OF MASS SPECTROMETRY

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

(2010) Davide Corti et al.   PLoS One

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens

(2010) K. J. Doores et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

(2010) T. Zhou et al.   SCIENCE

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function

(2010) Dirk Eggink et al.   VIROLOGY

A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals

(2010) Laura M. Walker et al.   PLoS Pathogens

Protease Cleavage Sites in HIV-1 gp120 Recognized by Antigen Processing Enzymes Are Conserved and Located at Receptor Binding Sites

(2009) B. Yu et al.   JOURNAL OF VIROLOGY

Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies

(2009) S. M. O'Rourke et al.   JOURNAL OF VIROLOGY

Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables

(2009) N. A. Doria-Rose et al.   JOURNAL OF VIROLOGY

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

(2009) M. D. Simek et al.   JOURNAL OF VIROLOGY

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

(2009) Johannes F. Scheid et al.   NATURE

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

(2009) Leonidas Stamatatos et al.   NATURE MEDICINE

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Fc receptor-mediated antiviral antibodies

(2009) Donald N Forthal et al.   Current Opinion in HIV and AIDS

Recent developments in the MAFFT multiple sequence alignment program

(2008) K. Katoh et al.   BRIEFINGS IN BIOINFORMATICS

Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection

(2008) D. N. Sather et al.   JOURNAL OF VIROLOGY

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

(2008) James Arthos et al.   NATURE IMMUNOLOGY